Dear Decision-Makers, Researchers, and Leaders in Public Health,

Herpes Simplex Virus (HSV) affects millions worldwide, causing not only physical pain but also significant emotional and mental distress. For decades, sufferers have relied on treatments that merely manage symptoms, leaving the underlying virus untouched and the stigma unchallenged. Now, there is hope in AB-5366—a promising antiviral therapy that could revolutionize how HSV is treated.

We, the undersigned, urgently call for the fast-tracking and funding of research and development for AB-5366. Early reports suggest that this treatment offers substantial benefits, including suppression of viral replication and potentially improved quality of life for those affected. While we await breakthroughs in gene-editing technologies for a permanent cure, AB-5366 provides a vital, near-term solution to alleviate the suffering of millions.

HSV sufferers cannot wait years for bureaucratic processes or underfunded studies to slowly bring effective treatments to market. The physical and mental toll of this virus is immediate and ongoing. Every day without action condemns millions to pain, shame, and stigma.

We demand:

1. Increased Public and Private Funding: Allocate resources to accelerate clinical trials and research into AB-5366 to ensure its safety, efficacy, and accessibility.

2. Expedited Regulatory Approval: Streamline the regulatory processes to bring this treatment to patients as quickly as possible without compromising safety.

3. Increased Awareness and Collaboration: Encourage collaboration between researchers, pharmaceutical companies, and public health agencies to prioritize HSV research and treatment.

This petition is a call for compassion and action. HSV sufferers deserve more than a lifetime of ineffective management and isolation. By fast-tracking AB-5366, we can bring real hope to millions and take a meaningful step toward addressing this widespread public health issue.

Sign this petition to demand immediate attention, funding, and action for the fast development of AB-5366. Together, we can make a difference.